Wilkins Investment Counsel Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 75,274 shares of the company’s stock after acquiring an additional 112 shares during the quarter. Johnson & Johnson accounts for approximately 3.1% of Wilkins Investment Counsel Inc.’s holdings, making the stock its 9th largest holding. Wilkins Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $11,667,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Moneta Group Investment Advisors LLC lifted its position in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $4,609,399,000. Morgan Stanley grew its holdings in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after acquiring an additional 3,849,148 shares during the period. Finally, Savant Capital LLC boosted its position in Johnson & Johnson by 8,568.8% in the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after purchasing an additional 3,588,251 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock worth $7,928,856. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Down 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the business posted $2.59 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.
Wall Street Analysts Forecast Growth
JNJ has been the subject of a number of recent analyst reports. Raymond James lifted their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a report on Monday, July 24th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, July 31st. Citigroup initiated coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective on the stock. Stifel Nicolaus upped their target price on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a research note on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $171.80.
Read Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Is Dividend Yield and How Do You Calculate It?
- On Holding Slips Into A More Comfortable Price PointÂ
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Growing Cannabis Stocks Ready To Bloom
- Insider Trading – What You Need to Know
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
